责任编辑：于健 SF069 德克萨斯州检察长办公室发表声明称，赛诺菲设立了向医疗保健提供者提供服务的项目，而这构成了违 反《德克萨斯州医疗保健项目欺诈预防法》的贿赂行为。 赛诺菲在一份声明中表示："这些服务的设置是为了符合相关的联邦和州法律，并且旨在为患者提供帮 助，而非影响医生的处方决策。" 美国德克萨斯州检察长肯·帕克斯顿（Ken Paxton）周四对赛诺菲提起诉讼，指控其该公司"向医疗供应 商行贿，以促使他们优先推荐其药品而非其他替代品"。 "政府的干预与本案的是非曲直无关，赛诺菲正在全力为此次诉讼辩护。"该公司补充道。 德克萨斯州将在此案中寻求超过100万美元的金钱救济，包括民事处罚，以及停止任何进一步非法行为 的禁令。 "政府的干预与本案的是非曲直无关，赛诺菲正在全力为此次诉讼辩护。"该公司补充道。 德克萨斯州将在此案中寻求超过100万美元的金钱救济，包括民事处罚，以及停止任何进一步非法行为 的禁令。 责任编辑：于健 SF069 美国德克萨斯州检察长肯·帕克斯顿（Ken Paxton）周四对赛诺菲提起诉讼，指控其该公司"向医疗供应 商行贿，以促使他们优先推荐其药品而非其他替代品"。 德克萨斯州检察长 ...

Core Viewpoint - The orthopedic industry is facing issues of high sales expenses and shrinking R&D investment, with major companies like Dabo Medical having sales expense ratios above the industry average [1] Group 1: Company Developments - Dabo Medical has recently made a new investment, fully acquiring Maikoste (Xiamen) Medical Equipment Co., Ltd. with a registered capital of 5 million yuan, focusing on professional technical services [1] Group 2: Stock Performance - Dabo Medical's stock price decreased from 50.14 yuan to 48.03 yuan over the past week, reflecting a decline of 2.66% and a volatility of 6.49%; on February 11, the stock fell by 1.58% with a net outflow of 10.377 million yuan [2] - As of February 12, the stock price slightly increased by 0.36% to 48.03 yuan, with a turnover rate of 0.60% and a trading volume of 82.96 million yuan; technical indicators suggest a downward trend [2] Group 3: Financial Performance - Dabo Medical expects a net profit attributable to shareholders for the year 2025 to be between 580 million yuan and 610 million yuan, representing a year-on-year growth of 62.55% to 70.96%; the non-recurring net profit is projected to grow by 59.42% to 69.93% [3] - The primary drivers of this growth are focused on core business, product innovation, and the advancement of international strategies, with a revenue of 1.876 billion yuan in the first three quarters of 2025, marking a year-on-year increase of 22.69% [3] Group 4: Institutional Insights - Institutions predict a net profit growth rate of 50.67% for 2025, with a slowdown to 16.88% in 2026; current institutional ratings are neutral, and the fund holding ratio is low at 0.88%, indicating moderate market attention [4]

智通财经注意到，据嵩明县融媒消息，此前的2025年2月8日，嵩明县第十七届人大常委会召开第二十一 次会议。李俊森被免去嵩明县水务局局长职务。 本 期 编 辑 邢潭 2024年1月和3月，在李俊森的关照下，帮助当事人获得了较大的竞争优势，先后承揽了嵩明县水务局上 游水库除险加固工程项目和应急补水工程项目两个项目4个标段的招标代理工作并收取招标代理费用， 实际获利112651.92元，违法所得为112651.92元。 大华建设项目管理有限公司云南分公司成立于2018年，经营范围为接受公司委托在公司经营范围和期限 内开展经营活动。 盘龙区市场监督管理局认为，依据《中华人民共和国反不正当竞争法》第十九条"经营者违反本法第七 条规定贿赂他人的，由监督检查部门没收违法所得，处十万元以上三百万元以下的罚款。情节严重的， 吊销营业执照。"的规定，对当事人作减轻行政处罚如下：没收112651.92元；罚款20000元。以上1、2 项罚没款合计132651.92元。 智通财经记者 史凭 2月4日，昆明市盘龙区市场监督管理局对大华建设项目管理有限公司云南分公司作出罚没13.2万余元的 行政处罚。经查，该公司为维系与嵩明县水务局原局 ...

智通财经注意到，在从重处罚案例中，"某制药公司商业贿赂从重处罚案"入选。 据介绍，某制药公司为涉案药品地氯雷他定胶囊的生产厂家，为了维持涉案药品在杭州桐庐县某医院的 销量，委托庄某进行推广，与该医院工作人员王某约定：由王某负责涉案药品在医院的持续采购，并向 王某支付回扣。 2017年6月20日至2019年6月14日期间，通过王某运作，该医院共计采购涉案药品2万余盒，采购金额120 余万元。王某收到涉案药品回扣款共计58万余元。该公司的行为违反《中华人民共和国反不正当竞争 法》相关规定，构成商业贿赂违法行为。 案件调查过程中，杭州市市场监管局先后四次向当事人送达《限期提供材料通知书》，要求提供涉案药 品的成本核算表、利润统计表等相关财务数据材料，并派专人赴广东省当面与当事人进行沟通，但其均 不予提供，导致其违法所得无法计算，严重阻碍行政执法人员依法执行职务。 近日，长三角三省一市市场监管部门围绕不予处罚、减轻处罚、从轻处罚、一般处罚和从重处罚五个裁 量阶次，联合发布一批规范涉企执法裁量权行使典型案例。 该批案例共12个，涵盖反不正当竞争、价格、食品安全、广告、特种设备安全、商标侵权等执法领域， 旨在推动长三角地 ...

Core Viewpoint - In 2025, Tencent's Anti-Fraud Investigation Department identified and dealt with over 70 cases of violations of the "Tencent High Voltage Line," resulting in the dismissal of over 90 individuals, with more than 20 being referred to law enforcement for criminal charges [1][2][3]. Summary by Sections Cases of Asset Misappropriation - He Yongkang from IEG Quality Management Department was found guilty of embezzling company assets and sentenced to 1 year and 2 months in prison, along with a fine of 20,000 RMB [1]. - Qin Yuan from CSIG Smart Industry Department was also convicted of asset misappropriation, receiving a 6-month prison sentence and a fine of 40,000 RMB [1]. - Ye Huahua from the subsidiary Nuclear Entertainment Game Interactive Center was sentenced to 3 years in prison and fined 100,000 RMB for similar offenses [2]. - Wang Mengwei from the subsidiary Tengzhuo R&D Center received a 5-month detention with an 8-month probation and a fine of 10,000 RMB for misappropriating assets [2]. - Multiple individuals from various departments, including CDG and PCG, were found guilty of similar offenses, leading to their dismissal and blacklisting [3][4][5]. Cases of Bribery - Li Xiang from CDG Advertising Marketing Service Line was involved in bribery by soliciting benefits from external companies, leading to his dismissal and referral to law enforcement [2]. - Liu Xiankai and Lin Haiqiang from the former PCG Value-Added Products Department were also implicated in bribery, resulting in their dismissal and blacklisting [3][4]. - Chen Si from CSIG East District Business Department and other employees were similarly found guilty of soliciting benefits from external companies, leading to their dismissal and legal action [3][4]. Theft Cases - Tian Chuanwu from CSIG Cloud Products Department was charged with theft of company assets, resulting in his dismissal and referral to law enforcement [5]. - Mai Jinming from CSIG Information Platform and Service Line was also found guilty of theft, leading to similar consequences [5].

Group 1 - The core issue highlighted is a long-term bribery case involving a sales representative from a medical polymer products company, which has exposed systemic corruption within the healthcare sector, particularly at the Pu'er People's Hospital [1][4] - The bribery network spanned over 15 departments within the hospital, implicating various levels of personnel, including financial directors and clinical department heads, indicating a widespread issue of collective bribery in the medical industry [1][4] - The National Healthcare Security Administration (NHSA) has publicly addressed this case to signal a commitment to tackling corruption by focusing on bribery entities and enforcing legal accountability across the entire chain [1][3] Group 2 - During the "14th Five-Year Plan" period, China has established the largest medical security network globally, significantly reducing the burden of medical expenses for the public and improving overall health levels [3] - Continuous efforts in anti-corruption within the medical sector are seen as crucial for maintaining a healthy industry ecosystem and ensuring the protection of public interests [3][9] - The NHSA has been actively reporting on cases of medical commercial bribery, emphasizing the need for stringent oversight on key positions and processes to strengthen anti-corruption measures [6][9] Group 3 - The bribery case involved a total of over 1.19 million yuan in bribes, with the pediatric department receiving the highest kickbacks, indicating a deep entrenchment of corrupt practices at various levels of hospital operations [5][4] - The NHSA has initiated centralized procurement measures for medical consumables to eliminate inflated pricing and reduce the financial burden on patients, addressing the root causes of corruption in the industry [5][8] - Recent cases of bribery in the medical equipment sector have also been reported, showcasing a broader trend of corruption that the NHSA is actively working to combat [7][8]

Core Viewpoint - The article highlights a case of commercial bribery involving Shanghai Haiyilai Consulting Management Partnership, which engaged in unethical practices to promote a specific drug, leading to administrative penalties and potential impacts on the involved companies' reputations and operations [2][3][4][5] Group 1: Company Actions and Penalties - Shanghai Haiyilai Consulting Management Partnership was found to have paid improper benefits to a clinical doctor to influence prescription behavior for the drug "Dahansuan Sodium Injection" [2] - The company received a total service income of 868,677 yuan from Shanghai Hongjian Pharmaceutical Co., and was fined 300,000 yuan by the Shanghai Putuo District Market Supervision Administration for commercial bribery [3] - The sales promotion director of Haiyilai promised the doctor a "benefit fee" for increased prescriptions, resulting in a total transfer of 35,046 yuan over four transactions [2][3] Group 2: Implications for Related Companies - The case has implications for Hebei Changshan Biochemical Pharmaceutical Co., which is linked to the drug involved and is a publicly listed company in China [3] - The annual sales of "Dahansuan Sodium Injection" exceed 170 million yuan, with a reported 26.68% year-on-year increase in sales volume, although revenue remained stable due to price declines [3] - The National Healthcare Security Administration has established a credit evaluation system since 2020 to assess pharmaceutical companies involved in commercial bribery, which may affect Changshan Pharmaceutical's credit rating in drug procurement [4][5]

Core Viewpoint - The National Medical Insurance Administration has announced a commercial bribery case involving a doctor from a women's and children's hospital in Shanghai, who received a benefit fee of 35,000 yuan for prescribing a drug, leading to a fine of 300,000 yuan for the involved company, Shanghai Haiyilai Enterprise Consulting Management Partnership [1][2] Group 1 - The involved company, Haiyilai, signed a one-year information service agreement with Hongjian Pharmaceutical Co., Ltd. to promote the drug "Dahansuan Sodium Injection" (brand name: Wanmai Ning) in Shanghai [1] - Haiyilai promised to maintain and increase the total sales of Wanmai Ning in Shanghai in exchange for the marketing service contract [1] - The sales promotion director and shareholder of Haiyilai promised the doctor a benefit fee for prescribing the drug, resulting in a total of 18,275 units prescribed during the year [1] Group 2 - The total income from market promotion and information services for Wanmai Ning in 2023 was 868,677 yuan [1] - The market supervision authority determined that Haiyilai's actions constituted commercial bribery, violating the Anti-Unfair Competition Law of the People's Republic of China [2] - An administrative penalty of 300,000 yuan was imposed on Haiyilai for its actions [2]

Core Points - The Shanghai Pudong New District Market Supervision Administration has imposed an administrative penalty of 400,000 RMB on Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd. for commercial bribery related to the promotion of the drug "Jiuqi Yi" (Mannitol Capsules) [1][2] - The company engaged in systematic and covert practices to influence doctors' prescription decisions by providing "lecture fees" and hosting banquets, starting from July 2022 until July 2024 [1][2] Summary by Sections Administrative Penalty - Green Valley Pharmaceutical was fined 400,000 RMB for violating the Pharmaceutical Administration Law by providing improper benefits to physicians [2] - The company conducted 587 academic meetings during the two-year period, with total payments amounting to 609,800 RMB for lecture fees and 223,600 RMB for dining expenses [2] Regulatory Findings - The regulatory body found no direct correlation between the payments made and the procurement amounts of "Jiuqi Yi" at the hospitals involved, leading to no recognition of illegal gains [2] - The actions of Green Valley Pharmaceutical were deemed to constitute commercial bribery, violating Article 88 of the Pharmaceutical Administration Law [2] Mitigating Factors - The regulatory authority considered the duration and severity of the violations, but also noted that this was the company's first offense and that it cooperated with the investigation and ceased the illegal payments [2] - The penalty was determined to be lighter due to the company's corrective actions following the incident [2] Operational Changes - In June 2023, Green Valley Pharmaceutical announced the closure of offices and production areas related to Mannitol Capsules, with operations halted as of May 30, 2025, due to the expiration of the drug's registration certificate [3]

Core Viewpoint - The article discusses the legal case involving Luo Xinwen, the former Party Secretary and General Manager of Dongfeng Consulting, who was sentenced to seven years in prison for multiple crimes, including bribery and collusion in bidding, with Liu Aisen, the Chairman and General Manager of Sen Te Co., Ltd., being implicated in the bribery [2][18]. Group 1: Legal Proceedings - Luo Xinwen was sentenced to seven years in prison and fined 620,000 yuan for six crimes, including bribery and collusion in bidding [2][18]. - The court found that Liu Aisen, the Chairman of Sen Te Co., Ltd., bribed Luo with 300,000 yuan to maintain favorable relations for future bidding opportunities [5][9]. - The case involved multiple instances of Sen Te Co., Ltd. winning bids through collusion with Luo and his company, Dongfeng Engineering Consulting [10][12]. Group 2: Company Background - Sen Te Co., Ltd. specializes in the design, manufacturing, and installation of metal guardrails and has been recognized as a "hidden champion" in the construction metal enclosure system sector in China [9]. - The company has been actively developing Building Integrated Photovoltaics (BIPV) business in recent years [9]. - As of June 2025, Liu Aisen held 25.06% of Sen Te Co., Ltd.'s shares, making him the largest shareholder [8].